Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organogenesis Holdings (ORGO) Preferred Stock Liabilities (2016 - 2025)

Organogenesis Holdings (ORGO) has 5 years of Preferred Stock Liabilities data on record, last reported at $133.8 million in Q4 2025.

  • For Q4 2025, Preferred Stock Liabilities rose 9.29% year-over-year to $133.8 million; the TTM value through Dec 2025 reached $133.8 million, up 9.29%, while the annual FY2025 figure was $133.8 million, 9.29% up from the prior year.
  • Preferred Stock Liabilities reached $133.8 million in Q4 2025 per ORGO's latest filing, up from $130.9 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $133.8 million in Q4 2025 and bottomed at $122.4 million in Q4 2024.